OncoMatch/Clinical Trials/NCT07306156
GP350 CAR-T for Relapse/Refractory and Epstein-Barr Virus Infection Associated Lymphoid Neoplasms
Is NCT07306156 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies GP350 CAR-T for ebv associated lymphoid neoplasms.
Treatment: GP350 CAR-T — This is a Phase 1/Phase 2 open-label, single-arm clinical study of GP350 CAR-T for Relapse/Refractory and Epstein-Barr virus infection associated lymphoid neoplasms. Each participant will undergo leukapheresis after enrolment, receive treatment of the conditioning chemotherapy, and an intravenous infusion of CAR-T cells. Each participant will proceed through the following study procedures: * Screening * Enrollment/Leukapheresis * Conditioning chemotherapy * CAR T treatment * Post-treatment assessment * Long-term follow-up
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: GP350 positivity (≥10% of tumor cells) (≥10% of tumor cells)
Tumor cell GP350 positivity (≥10% of tumor cells by immunohistochemistry or flow cytometry)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Lab requirements
Blood counts
ANC ≥1.0×10⁹/L; Hemoglobin >60 g/L; CD3+ T-cell count >0.5×10⁹/L; Platelet count >30×10⁹/L
Kidney function
Creatinine clearance ≥60 mL/min
Liver function
ALT/AST ≤2× ULN; Total bilirubin ≤2× ULN
Cardiac function
LVEF ≥50%, no pericardial effusion, no clinically significant ECG abnormalities; NYHA Class III or IV congestive heart failure [excluded]; Myocardial infarction or coronary artery bypass grafting within the past 6 months [excluded]; Clinically significant ventricular arrhythmia or unexplained syncope [excluded]; History of severe non-ischemic cardiomyopathy [excluded]; Cardiac insufficiency (LVEF <45%) within 8 weeks prior to apheresis [excluded]
Creatinine clearance ≥60 mL/min; ALT/AST ≤2× ULN; Total bilirubin ≤2× ULN; LVEF ≥50%, no pericardial effusion, and no clinically significant ECG abnormalities; Minimal or no pleural/ascitic fluid; Oxygen saturation ≥95%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07306156 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require GP350?
Yes, GP350 positivity (≥10% of tumor cells) is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify